Log in

NASDAQ:VSTMVerastem Stock Price, Forecast & News

+0.10 (+5.68 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $1.86
50-Day Range
MA: $2.44
52-Week Range
Now: $1.86
Volume5.78 million shs
Average Volume9.12 million shs
Market Capitalization$302.31 million
P/E RatioN/A
Dividend YieldN/A
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.
Read More
Verastem logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VSTM



Sales & Book Value

Annual Sales$17.46 million
Book Value$0.76 per share


Net Income$-149,210,000.00
Net Margins-715.40%


Market Cap$302.31 million
Next Earnings Date8/6/2020 (Estimated)

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Verastem (NASDAQ:VSTM) Frequently Asked Questions

How has Verastem's stock been impacted by COVID-19 (Coronavirus)?

Verastem's stock was trading at $2.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VSTM stock has decreased by 23.8% and is now trading at $1.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Verastem?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Verastem.

When is Verastem's next earnings date?

Verastem is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Verastem.

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.13. The biopharmaceutical company had revenue of $5.06 million for the quarter, compared to the consensus estimate of $3.14 million. Verastem had a negative net margin of 715.40% and a negative return on equity of 282.13%. View Verastem's earnings history.

What price target have analysts set for VSTM?

4 brokerages have issued 1 year price targets for Verastem's stock. Their forecasts range from $3.00 to $9.00. On average, they anticipate Verastem's share price to reach $6.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price. View analysts' price targets for Verastem.

Has Verastem been receiving favorable news coverage?

Media headlines about VSTM stock have trended negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Verastem earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutVerastem.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP) and TG Therapeutics (TGTX).

Who are Verastem's key executives?

Verastem's management team includes the following people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 55)
  • Mr. Robert E. Gagnon, Chief Financial Officer (Age 45)
  • Mr. Joseph M. Lobacki, Exec. VP & Chief Commercial Officer (Age 61)
  • Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 65)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Who are Verastem's major shareholders?

Verastem's stock is owned by many different institutional and retail investors. Top institutional investors include RA Capital Management L.P. (11.45%), Vivo Capital LLC (5.01%), Ikarian Capital LLC (3.23%), VR Adviser LLC (2.29%), BlackRock Inc. (1.05%) and Ghost Tree Capital LLC (0.92%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Ra Capital Management, LP, Robert Forrester, Steven H Bloom and Timothy J Barberich. View institutional ownership trends for Verastem.

Which major investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, BlackRock Inc., Morgan Stanley, Samalin Investment Counsel LLC, UBS Group AG, Howland Capital Management LLC, Howland Capital Management LLC, and Raymond James & Associates. View insider buying and selling activity for Verastem.

Which major investors are buying Verastem stock?

VSTM stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Vivo Capital LLC, Ikarian Capital LLC, VR Adviser LLC, Ghost Tree Capital LLC, EAM Investors LLC, Matisse Capital, and Telemetry Investments L.L.C.. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom, and Timothy J Barberich. View insider buying and selling activity for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $1.86.

How big of a company is Verastem?

Verastem has a market capitalization of $302.31 million and generates $17.46 million in revenue each year. The biopharmaceutical company earns $-149,210,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Verastem employs 169 workers across the globe.

What is Verastem's official website?

The official website for Verastem is www.verastem.com.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.